Sumanta K. Pal, MD, and Neeraj Agarwal, MD, on Prostate Cancer: The Talapro-2 Trial

2018 ASCO Annual Meeting
Tweet this page

Sumanta K. Pal, MD, of the City of Hope, and Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discuss the ongoing phase III Talapro-2 study of talazoparib with background enzalutamide in metastatic castration-resistant prostate cancer with DNA damage–repair deficiencies (Abstract TPS5091).

Jun

Today In Oncology

Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%

Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients

Total Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma

ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy

FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer

;